Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letaplimab combination therapy in advanced malignancies
NCT04861948Phase 1Terminated
- Sponsor
- Innovent Biologics
- Start
- May 2021
- Primary completion
- Jul 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of letaplimab in solid tumor, lung adenocarcinoma and osteosarcoma (OS) (4 cohorts), sponsored by Innovent Biologics. Primary endpoints: Objective Response Rate at 24 months and Adverse Events at 24 months. Started May 2021; status: terminated.
02
Drugs
letaplimab
03
Conditions
solid tumorlung adenocarcinomaosteosarcoma (OS)
Beyond the preview
Go deeper on NCT04861948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04861948.